Fund Overlap
See which holdings any two equity ETFs have in common, along with top differences in exposure.
For overlap across multiple ETFs use Portfolio Builder
12
Number of overlapping holdings
30.0%
% of HRTS's 41 holdings also in CANC
25.0%
% of CANC's 48 holdings also in HRTS
Overlap by Weight
Sector Drift (HRTS minus CANC)
Overlapping Holdings
Top 5 only shown here. Please log-in or sign up for a Basic (Free) membership to view the complete list.
| Company | Weight in HRTS |
Weight in CANC |
Overlap | |
|---|---|---|---|---|
 |
ELI LILLY & CO | 10.9% | 5.4% | 5.4% |
|
BRIDGEBIO PHARMA, INC. | 4.3% | 4.5% | 4.3% |
 |
ASTRAZENECA PLC | 4.0% | 4.2% | 4.0% |
 |
ROCHE HOLDINGS LTD-SPONS ADR | 3.9% | 5.1% | 3.9% |
|
NOVARTIS AG | 3.1% | 4.3% | 3.1% |
Position Highlights (Non-Overlapping Exposures)
HRTS Overweight Relative to CANC
|
UNITEDHEALTH GROUP INC | 5.6% |
|
ELI LILLY & CO | 5.5% |
|
ABBOTT LABORATORIES | 4.0% |
 |
NOVO NORDISK A/S-B | 3.9% |
|
VERTEX PHARMACEUTICALS INC | 3.6% |
|
BOSTON SCIENTIFIC CORP | 3.1% |
 |
MEDTRONIC PLC | 3.0% |
|
THERMO FISHER SCIENTIFIC INC | 2.8% |
|
CRINETICS PHARMACEUTICALS INC | 2.8% |
|
CYTOKINETICS INC | 2.3% |
HRTS Underweight Relative to CANC
|
REVOLUTION MEDICINES, INC. | -5.7% |
|
NUVALENT, INC. CLASS A | -3.9% |
|
SUMMIT THERAPEUTICS INC | -3.9% |
|
EXELIXIS INC | -3.8% |
|
GENMAB A/S SPONSORED ADR | -3.4% |
 |
MERUS N.V. | -3.2% |
 |
ZAI LAB LTD. UNSPONSORED ADR | -3.0% |
|
BLUEPRINT MEDICINES CORP. | -2.9% |
|
ARCELLX, INC. | -2.9% |
 |
DAIICHI SANKYO CO LTD | -2.9% |